Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 159 of the 242 references it cites were found in a registry or an index; 114 of the 184 sources its claims cite were checked for support.

Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review

Open access

Abstract

This review highlights the role of targeted nanoparticles as effective drug carriers across the BBB for both early and late stages of AD.

Overview

CoChat Summary

## TL;DR

This review argues that targeted nanoparticles can help overcome the blood–brain barrier in Alzheimer’s disease by improving brain delivery, targeting amyloid/tau pathology, and enabling stage-specific therapy. It emphasizes that early and late AD require different nanoparticle strategies, while safety, clearance, and clinical translation remain major barriers.

## Key findings

  • Targeted nanoparticles are presented as a way to improve brain drug bioavailability and enable stage-specific intervention across early and late Alzheimer’s disease.
  • The review identifies two main BBB-crossing mechanisms for nanoparticle delivery: receptor-mediated transcytosis (RMT) and adsorptive-mediated transcytosis (AMT).
  • In early AD, the BBB is described as mostly intact with only minor permeability changes, making receptor-targeted nanoparticles especially relevant; in late AD, BBB disruption increases nonspecific permeability and toxicity risk.
  • The paper highlights that lipid-based and polymeric nanoparticles are the most promising platforms because of their biocompatibility, versatility, and surface modifiability, while metallic nanoparticles raise more toxicity concerns.
  • It reports specific preclinical examples, including a multifunctional nanoformulation that in a transgenic mouse model reduced Aβ deposition, enhanced autophagy, and improved cognitive performance, and another nano-cleaner that promoted microglia-mediated Aβ clearance and regulated neuroinflammation.
  • For safety, it notes quantitative toxicity examples: silver nanoparticles were reported to cause significant neurotoxicity above 10 μg/ml in primary cortical neurons, whereas PLGA nanoparticles showed minimal cytotoxic effects up to 100 μg/ml in neuronal and glial cultures.

## Methods

  • Narrative review of literature on nanoparticle-based drug delivery across the BBB in Alzheimer’s disease, with emphasis on early vs. late disease stages.
  • Synthesizes published findings on nanoparticle classes (lipid-based, polymeric, inorganic, and biological/exosomal systems), BBB transport mechanisms, targeting strategies, safety/toxicity, and diagnostic/theragnostic applications.
  • Uses comparative, mechanism-focused analysis rather than original experimental data; the text references preclinical studies, animal models, cell culture studies, and clinical trial reports.

## Limitations

  • The paper states that long-term safety, immunogenicity, biodistribution, clearance kinetics, and pharmacokinetics remain insufficiently characterized.
  • It states that clinical translation is limited by poor BBB penetration, peripheral accumulation, suboptimal dosing, protein corona effects, and trial design issues, and that only a few nanoparticle formulations have advanced into clinical trials.
  • Evident from the text: this is a review, so it does not present new experimental data or a systematic quantitative meta-analysis of efficacy across nanoparticle types.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s12035-025-05417-z

Cites

159 of 242 references verified43 citation errors · 40 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Stage-specific Therapeutic Strategies Using NPs in AD
Fig. 1 Stage-specific Therapeutic Strategies Using NPs in ADCC BY-NC-ND · PubMed Central
Fig. 2 Blood–brain Barrier Changes in Early vs Late Alzheimer’s Disease and the Corresponding Nanoparticle Strategies for each Stage
Fig. 2 Blood–brain Barrier Changes in Early vs Late Alzheimer’s Disease and the Corresponding Nanoparticle Strategies for each StageCC BY-NC-ND · PubMed Central
Fig. 3 Mechanisms of Nanoparticle Transcytosis across the Blood–brain Barrier in Early- and Late-stage Alzheimer’s Disease
Fig. 3 Mechanisms of Nanoparticle Transcytosis across the Blood–brain Barrier in Early- and Late-stage Alzheimer’s DiseaseCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

68 Valid · 21 Not valid · 39 Not checked · 7 Own results and interpretations

52 more claims · 31 with their cited sources checked

Create a free account to see all 135 claims and to verify the 15 references still open.

See all claims — free account
  • It may state two separate claims as one. 73
  • The quote only partly states this claim. 1
  • Probably not a substantial claim. 11

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 156 references

Research works printed but not linked: 13

  1. [Zhang C, Tanzi RE (2012) Natural Modulators of Amyloid-Beta Precursor Protein Processing. Curr Alzheimer Res 9(9):1101–9 https://doi.org/10.2174/156720512803251327 · doi:10.2174/156720512803251327
  2. Al Asmari AK, Ullah Z, Tariq M, Fatani A (2016) Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil. Drug Des Devel Ther 10:205–215. https://doi.org/10.2147/DDDT.S95582 · doi:10.2147/dddt.s95582
  3. Nanoparticles for direct nose-to-brain delivery of drugs. Europe PMC. Available from: https://europepmc.org/article/med/19555750
  4. Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L (2024) Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther 9(1):1–29. https://doi.org/10.1038/s41392-024-01234-9 · doi:10.1038/s41392-024-01234-9
  5. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM (2016) PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 99(Pt A):28–51. https://doi.org/10.1016/j.addr.2015.09.012 · DOI · Paper page
  6. Capela JP, Schifano F, Krsek A, Baticic L (2024) Nanotechnology-driven therapeutic innovations in neurodegenerative disorders: a focus on Alzheimer’s and Parkinson’s disease. Future Pharmacol 4(2):352–379. https://doi.org/10.3390/futurepharma4020020 · doi:10.3390/futurepharma4020020
  7. Sweeney MD, Sagare AP, Zlokovic BV (2018) Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol 14(3):133–150. https://doi.org/10.1038/nrneurol.2017.188 · DOI · Paper page
  8. Tosi G, Pederzoli F, Belletti D, Vandelli MA, Forni F, Duskey JT et al (2019) Nanomedicine in Alzheimer’s disease: amyloid beta targeting strategy. Prog Brain Res 245:57–88. https://doi.org/10.1016/bs.pbr.2018.11.006 · doi:10.1016/bs.pbr.2018.11.006
  9. Sharma HS, Hussain S, Schlager J, Ali SF, Sharma A (2010) Influence of nanoparticles on blood-brain barrier permeability and brain edema formation in rats. Acta Neurochir Suppl 106:359–364. https://doi.org/10.1007/978-3-211-99374-5_58 · doi:10.1007/978-3-211-99374-5_58
  10. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM (2015) PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 99(Pt A):28–51. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4798869/. Accessed 10 Aug 2025 · DOI · Paper page
  11. Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5(4):505–515. https://doi.org/10.1021/mp800051m · DOI · Paper page
  12. Tripathi P, Shukla P, Bieberich E (2022) Theranostic applications of nanomaterials in Alzheimer’s disease: a multifunctional approach. Curr Pharm Des 28(2):116–132. https://doi.org/10.2174/1381612827666220315111214 · doi:10.2174/1381612827666220315111214
  13. Vieira DB, Gamarra LF (2016) Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier. Int J Nanomedicine 11:5381–5414. https://doi.org/10.2147/IJN.S107392 · doi:10.2147/ijn.s107392

Cited by

See all 60

Metadata

Authors
Kochman, U., Sitka, H., Kuźniar, J., Czaja, M., Kozubek, P., Beszłej, J. A., & Leszek, J.
Affiliations
Wroclaw Medical University (PL)
Corresponding author
Kochman, Urszula
Venue
Molecular Neurobiology
Published
2025-11-19
Volume
63
Issue
1
Pages
75-75
ISSN
  • 0893-7648 (ISSN-L)
  • 1559-1182
OpenAlex
W4416333752
Cited by
60
References
156
Citations by year
2026: 59 · 2025: 1
FWCI
3.47
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Neurobiology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
Alzheimer's disease, blood-brain barrier, targeted nanoparticles, nanoparticle drug delivery, early Alzheimer's disease, amyloid fibril formation, tau protein, neuroinflammation, oxidative stress, lipid nanoparticles, polymeric nanoparticles, inorganic nanoparticles, surface modification, receptor-mediated transcytosis, nanoparticle toxicity, biocompatibility, nanomedicine
MeSH terms
Alzheimer Disease, Animals, Blood-Brain Barrier, Drug Carriers, Humans, Drug Delivery Systems, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review. https://app.cochat.ai/papers/10.1007/s12035-025-05417-z
The paper
Kochman, U., Sitka, H., Kuźniar, J., Czaja, M., Kozubek, P., Beszłej, J. A., & Leszek, J. (2026). Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review. Molecular Neurobiology. https://doi.org/10.1007/s12035-025-05417-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.